Brief Report: Impact of Maintenance Pemetrexed Cessation on Clinical Outcomes of Patients With Metastatic Nonsquamous NSCLC

Introduction: Combination chemoimmunotherapy including pemetrexed and a PD(L)1 inhibitor is a common first-line systemic therapy approach for patients with metastatic nonsquamous NSCLC. Patients often discontinue maintenance pemetrexed due to adverse effects, and little is known about the impact of...

Descripció completa

Dades bibliogràfiques

Autors principals:	Shreya Bhatia, BS, Matthew Lu, MD, Spencer Lessans, MD, Michael Libre, BA, Heidi Chen, PhD, Wade T. Iams, MD
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2024-11-01
Col·lecció:	JTO Clinical and Research Reports
Matèries:	Non–small cell lung cancer Chemoimmunotherapy Pemetrexed Pembrolizumab
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2666364324000870
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!